Women with fibroids considering Saxenda should understand that while there is no evidence suggesting the medication worsens fibroid symptoms or promotes fibroid growth, the available evidence has limitations
Options such as Miralax (polyethylene glycol) or magnesium citrate can be used if needed with direction from your healthcare provider
Am J Hypertens 14:694698 Mancia G, Kreutz R, Brunstrm M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernndez-Alfonso MS, Halimi JM, Jrai Z, Jelakovi B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, de Van Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE (2023) 2023 ESH guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)
However, if you have any concerns or questions, feel free to reach out to our helpline
FDA has established clear transition periods for compounding pharmacies with the deadline for state-licensed pharmacies and outsourcing facilities to cease compounding tirzepatide on February 18, 2025 and March 19, 2025, respectively Patients should maintain close communication with healthcare providers during any transition References Disclaimer: This article is for informational purposes only and does not constitute medical advice
Dizziness while on tirzepatide can be caused by many different factors
